Δημοσιεύσεις

2025

Long-term outcomes from pembrolizumab monotherapy in patients with ad-vanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

Cortellini A, Garbo E, La Cava G, Citarella F, Santo V, Brunetti L, Pinato DJ, Naidoo J, Loza M, Genova C, Gettinger S, Kim SY, Jayakrishnan R, Zarif TE, Russano M, Pecci F, Di Federico A, Montrone M, Owen DH, Signorelli D, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Yendamuri S, Grossi F, Josephides E, Tomasik B, Giusti R, Bria E, Sebastian M, Rost M, Acker F, Landi L, Mazzoni F, Morabito A, Leonetti A, Cantini L, Mountzios G, Kalvapudi S, O'Reilly D, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Piedra A, Cortinovis DL, Tonini G, Minuti G, Mezquita L, Gorria T, Beninato T, Lo Russo G, PrelaJ A, De Giglio A, Biello F, Nana FA, Dingemans AC, Aerts JG, Ferrara R, Taher Hejleh A, Takada K, Naqash AR, Garassino MC, Wakelee HA, Nassar A, Ricciuti B, Soda P, Caruso CM, Guarrasi V. | Lung Cancer. 2025 Oct 16

Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer

Paz-Ares LG, Juan-Vidal O, Mountzios GS, Felip E, Reinmuth N, de Marinis F, Girard N, Patel VM, Takahama T, Owen SP, Reznick DM, Badin FB, Cicin I, Mekan S, Patel R, Zhang E, Karumanchi D, Garassino MC. | Future Oncol. 2025 Oct

Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final outcome, immunophenotypic and biomarker analysis of a multi-center phase II Hel-lenic Cooperative Oncology Group study

Linardou H, Papadopoulou K, Korfiatis N, Goussia A, Samantas E, Aravantinos G, Christopoulou A, Spathas N, Fountzilas E, Psyrri A, Koliou GA, Meditskou S, Kosmas E, Bobos M, Charchanti AV, Vamvakaris I, Koumarianou A, Bafaloukos D, Kosmidis P, Fountzilas G, Mountzios G. | Eur J Cancer. 2025 Oct 1

Transformer-based AI approach to unravel long-term, time-dependent prog-nostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: in-sights from the pembrolizumab 5-year global registry

Cortellini A, Santo V, Brunetti L, Garbo E, Pinato DJ, La Cava G, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Alessi JV, Montrone M, Owen DH, Ramella S, Signorelli D, Fidler MJ, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, D'Alessio A, Banna GL, Fulgenzi CAM, Grisanti S, Grossi F, D'Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Balachandran K, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Sforza V, Tiseo M, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Rocco D, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O'Reilly D, Fitzpatrick O, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Piedra A, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Lo Russo G, Prelaj A, De Giglio A, Rogado J, Moliner L, Nadal E, Biello F, Nana FA, Dingemans AM, Aerts JGJV, Ferrara R, Abu Hejleh T, Takada K, Naqash AR, Garassi… See abstract for full author list ➔ | J Immunother Cancer. 2025 Sep 29

De-escalation strategies with targeted therapies in non-small cell lung can-cer

Bortolot M, Remon J, Bironzo P, Cortiula F, Menis J, Chan SW, van Geel R, Reguart N, Arrieta O, Mountzios G, Dingemans AC, Besse B, Hendriks LEL. | Cancer Treat Rev. 2025 Sep

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung can-cer (KRYSTAL-12): a randomised, open-label, phase 3 trial

Barlesi F, Yao W, Duruisseaux M, Doucet L, Martínez AA, Gregorc V, Juan-Vidal O, Lu S, De Bondt C, de Marinis F, Linardou H, Kim YC, Jotte R, Felip E, Lo Russo G, Reck M, Michenzie MF, Yang W, Meade JN, Korytowsky B, Mok TSK; KRYSTAL-12 Investigators. | Lancet. 2025 Aug 9

Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer

Skoulidis F, Li BT, de Langen AJ, Hong DS, Lena H, Wolf J, Dy GK, Curioni Fontecedro A, Tomasini P, Velcheti V, van der Wekken AJ, Dooms C, Paz-Ares Rodriguez L, Mountzios G, Sacher A, Nadal E, Couraud S, Kim SW, O'Byrne K, Rocco D, Toyozawa R, Chmielewska I, Lindsay CR, Hindoyan A, Mukundan L, Wilmanski T, Anderson A, Ardito-Abraham C, Pati A, Reddy A, Mehta B, Schuler M. | Nat Med. 2025 Aug

Beyond Programmed Death-Ligand 1: Gut Microbiome Composition as a Bi-omarker For First-Line Chemoimmunotherapy in Advanced NSCLC

Koutoukoglou P, Mountzios G. | J Thorac Oncol. 2025 Jul

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Mountzios G, Sun L, Cho BC, Demirci U, Baka S, Gümüş M, Lugini A, Zhu B, Yu Y, Korantzis I, Han JY, Ciuleanu TE, Ahn MJ, Rocha P, Mazières J, Lau SCM, Schuler M, Blackhall F, Yoshida T, Owonikoko TK, Paz-Ares L, Jiang T, Hamidi A, Gauto D, Recondo G, Rudin CM; DeLLphi-304 Investiga-tors. | N Engl J Med. 2025 Jul 24

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary

de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L; CodeBreaK 200 Investigators. | Future Oncol. 2025 Apr

De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence?

Remon J, Bortolot M, Bironzo P, Cortiula F, Menis J, Brandao M, Naidoo J, van Geel R, Reguart N, Arrieta O, Mountzios G, Hendriks LEL, Besse B. | J Clin Oncol. 2025 Mar 20

Exploration of Novel Anticancerous Agents Targeting Human Aurora Kinase C

Gupta D, Shukla PK, Chowdhury S, Kumari S, Kaur P, Kumar M. | J Cell Biochem. 2025 Mar

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

Cortellini A, Brunetti L, Di Fazio GR, Garbo E, Pinato DJ, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi JV, Montrone M, Owen DH, Signorelli D, Fidler MJ, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika NO, Napolitano A, Fulgenzi CAM, Grisanti S, Grossi F, D'Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O'Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Lo Russo G, Rogado J, Moliner L, Biello F, Aboubakar Nana F, Dingemans AM, Aerts JGJV, Ferrara R, Torri V, Hejleh TA, Takada K, Naqash AR, Garassino M, Peters … See abstract for full author list ➔ | J Immunother Cancer. 2025 Feb 4

Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target

Mountzios G, Saw SPL, Hendriks L, Menis J, Cascone T, Arrieta O, Naidoo J, Koutoukoglou P, Cani M, Lefevre A, Addeo A, Peters S, Remon J. | Cancer Treat Rev. 2025 Mar

Tarlatamab in Small-Cell Lung Cancer. Reply

Rudin CM, Mountzios G. | N Engl J Med. 2025 Oct 2

2024

Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC

Hochmair MJ, Vermaelen K, Mountzios G, Carcereny E, Dooms C, Lee SH, Morocz E, Kato T, Ciuleanu TE, Dy GK, Parente B, O'Byrne KJ, Chu QS, Castro Junior G, Girard N, Snyder W, Tran Q, Kormany W, Houk B, Mehta B, Curioni-Fontecedro A. | Eur J Cancer. 2024 Sep

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies

Lavaud P, Bortolot M, Zullo L, O'Reilly D, Naidoo J, Mountzios G, Mercier O, Hendriks LEL, Remon J. | Cancers (Basel). 2024 Aug 6

Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)

Janzic U, Maimon Rabinovich N, Shalata W, Kian W, Szymczak K, Dziadziuszko R, Jakopovic M, Mountzios G, Pluzanski A, Araujo A, Charpidou A, Daher S, Agbarya A. | Curr Oncol. 2024 Jul 30

CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

Neal J, Pavlakis N, Kim SW, Goto Y, Lim SM, Mountzios G, Fountzilas E, Mochalova A, Christoph DC, Bearz A, Quantin X, Palmero R, Antic V, Chun E, Edubilli TR, Lin YC, Huseni M, Ballinger M, Graupner V, Curran D, Vervaet P, Newsom-Davis T. | J Clin Oncol. 2024 Jul 10

Beyond Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer: New Frontiers, New Challenges

Mountzios G, Naidoo J, Wang C, Creelan BC, Trotier DC, Campbell TC, Pe-ters S. | Am Soc Clin Oncol Educ Book. 2024 Jun

Cancer biomarkers: Emerging trends and clinical implications for personal-ized treatment

Passaro A, Al Bakir M, Hamilton EG, Diehn M, André F, Roy-Chowdhuri S, Mountzios G, Wistuba II, Swanton C, Peters S. | Cell. 2024 Mar 28

Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges

Remon J, Saw SPL, Cortiula F, Singh PK, Menis J, Mountzios G, Hendriks LEL. | J Thorac Oncol. 2024 Feb

2023

First-line immunotherapy in non-small cell lung cancer: how to select and where to go

Mogavero A, Cantale O, Mollica V, Anpalakhan S, Addeo A, Mountzios G, Friedlaender A, Kanesvaran R, Novello S, Banna GL. | Expert Rev Respir Med. 2023 Dec

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Bustamante Alvarez J, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L; DeLLphi-301 Investigators. | N Engl J Med. 2023 Nov 30

Immune-checkpoint inhibition for resectable non-small-cell lung cancer - op-portunities and challenges

Mountzios G, Remon J, Hendriks LEL, García-Campelo R, Rolfo C, Van Schil P, Forde PM, Besse B, Subbiah V, Reck M, Soria JC, Peters S. | Nat Rev Clin Oncol. 2023 Oct

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. | Cancer Discov. 2023 Jul 7

Extending the EXOTIC Database to Allow the Recognition of Potential Causes of Exon 20-Mutated NSCLC

Mountzios G; EXOTIC Consortium. | JTO Clin Res Rep. 2023 Apr 13

MET alterations in NSCLC-Current Perspectives and Future Challenges

Remon J, Hendriks LEL, Mountzios G, García-Campelo R, Saw SPL, Uprety D, Recondo G, Villacampa G, Reck M. | J Thorac Oncol. 2023 Apr

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Sol-omon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L; CodeBreaK 200 Investigators. | Lancet. 2023 Feb 7

Cancer burden in adolescents and young adults in Europe

Trama A, Stark D, Bozovic-Spasojevic I, Gaspar N, Peccatori F, Toss A, Bernasconi A, Quarello P, Scheinemann K, Jezdic S, Blondeel A, Mountzios G, Bielack S, Saloustros E, Ferrari A. | ESMO Open. 2023 Feb 6

RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion

Aldea M, Marinello A, Duruisseaux M, Zrafi W, Conci N, Massa G, Metro G, Monnet I, Gomez PI, Tabbo F, Bria E, Guisier F, Vasseur D, Lindsay CR, Ponce S, Cousin S, Citarella F, Fallet V, Minatta JN, Eisert A, de Saint Basile H, Audigier-Valette C, Mezquita L, Calles A, Mountzios G, Tagliamento M, Masip JR, Raimbourg J, Terrisse S, Russo A, Cortinovis D, Rochigneux P, Pinato DJ, Cortellini A, Leonce C, Gazzah A, Ghigna MR, Ferrara R, Dall'Olio FG, Passiglia F, Ludovini V, Barlesi F, Felip E, Planchard D, Besse B. | J Thorac Oncol. 2023 Jan 13

2022

Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EX-OTIC Registry

Mountzios G, Planchard D, Metro G, Tsiouda D, Prelaj A, Lampaki S, Shalata W, Riudavets M, Christopoulos P, Girard N, Albarrán-Artahona V, Garcia Campelo R, Samitas K, Banna GL, Boukovinas I, Agbarya A, Koumarianou A, Perdikouri EI, Kosmidis P, Linardou H, Mauri D, Mavroudis D, Athanasiadis I, Kalofonos H, Xenidis N, Korantzis I, Ardavanis A, Rallis G, Bottiglieri A, Efthymiadis K, Oikonomopoulos G, Kokkalis A, Saloustros E, Tsoukalas N, Bartzi D, Economopoulou P, Psyrri A, Reck M, Lo Russo G. | JTO Clin Res Rep. 2022 Nov 20

MET alterations in NSCLC-Current Perspectives and Future Challenges

Remon J, Hendriks LEL, Mountzios G, García-Campelo R, Saw SPL, Uprety D, Recondo G, Villacampa G, Reck M. | J Thorac Oncol. 2022 Oct 29

Pembrolizumab Administration Frequency, Dose Exposure, and Toxicity: Is Switching Safe?

Mountzios G, Aggarwal C. | J Thorac Oncol. 2022 Oct

Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways

Mountzios G, Banna GL, Rolfo C. | Front Oncol. 2022 Sep 16

Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study

Dimitrakopoulos FI, Mountzios G, Christopoulos P, Papastergiou T, Elshiaty M, Daniello L, Zervas E, Agelaki S, Samantas E, Nikolaidi A, Athanasiadis I, Baka S, Syrigos K, Christopoulou A, Lianos E, Samitas K, Tsoukalas N, Perdikouri EI, Oikonomopoulos G, Kottorou A, Kalofonou F, Makatsoris T, Koutras A, Megalooikonomou V, Kalofonos H. | Ther Adv Med Oncol. 2022 Sep 8

Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece

Lampaki S, Mountzios G, Georgoulias V, Rapti A, Xanthakis I, Baka S, Mavroudis D, Samantas E, Athanasiadis E, Zagouri F, Charpidou A, Somarakis A, Papista C, Nikolaou A, Anastasopoulou E, Paparepa Z, Syrigos KN. | Future Oncol. 2022 Sep

The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations

Caglevic C, Rolfo C, Gil-Bazo I, Cardona A, Sapunar J, Hirsch FR, Gandara DR, Morgan G, Novello S, Garassino MC, Mountzios G, Leighl NB, Bretel D, Arrieta O, Addeo A, Liu SV, Corrales L, Subbiah V, Aboitiz F, Villarroel-Espindola F, Reyes-Cosmelli F, Morales R, Mahave M, Raez L, Alatorre J, Santos E, Ubillos L, Tan DSW, Zielinski C. | JCO Glob Oncol. 2022 Aug

Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis

Bestvina CM, Whisenant JG, Torri V, Cortellini A, Wakelee H, Peters S, Roca E, De Toma A, Hirsch FR, Mamdani H, Halmos B, Arrieta O, Metivier AC, Fidler MJ, Rogado J, Presley CJ, Mascaux C, Genova C, Blaquier JB, Addeo A, Finocchiaro G, Khan H, Mazieres J, Morgillo F, Bar J, Aujayeb A, Mountzios G, Scotti V, Grosso F, Geraedts E, Zhumagaliyeva AN, Horn L, Garassino MC, Baena J; TERAVOLT study group. | JTO Clin Res Rep. 2022 Aug

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease

Metro G, De Giglio A, Ricciuti B, Siringo M, Marinelli D, Gelibter A, Pecci F, Berardi R, Cantini L, Di Federico A, Andrini E, Mosca M, Lamberti G, Brambilla M, Mountzios G. | Drugs Context. 2022 Jul 29

Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies

Koulouris A, Tsagkaris C, Corriero AC, Metro G, Mountzios G. | Cancers (Basel). 2022 Jul 8

Lung cancer as a predominant feature in a patient with Peutz-Jeghers syndrome: Case report

Fostira F, Fountzilas E, Papadopoulou K, Karaiskos T, Mpatsi O, Pastelli N, Mountzios G, Konstantopoulou I, Fountzilas G. | Thorac Cancer. 2022 Jun

A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, Leighl NB, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Blaquier JB, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Garrido P, Khan H, Baggi A, Mascaux C, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Métivier AC, Falchero L, Felip E, Genova C, Mazieres J, Tapan U, Brahmer J, Bria E, Puri S, Popat S, Reckamp KL, Morgillo F, Nadal E, Mazzoni F, Agustoni F, Bar J, Grosso F, Avrillon V, Patel JD, Gomes F, Ibrahim E, Trama A, Bettini AC, Barlesi F, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V; TERAVOLT study group. | J Thorac Oncol. 2022 May

Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group

Fountzilas E, Lampaki S, Koliou GA, Koumarianou A, Levva S, Vagionas A, Christopoulou A, Laloysis A, Psyrri A, Binas I, Mountzios G, Kentepozidis N, Kotsakis A, Saloustros E, Boutis A, Nikolaidi A, Fountzilas G, Georgoulias V, Chrysanthidis M, Kotteas E, Vo H, Tsiatas M, Res E, Linardou H, Daoussis D, Bompolaki I, Andreadou A, Papaxoinis G, Spyratos D, Gogas H, Syrigos KN, Bafaloukos D. | Cancer Immunol Immunother. 2022 Feb

Evaluating Pancreatic and Biliary Neoplasms with Small Biopsy-Based Next Generation Sequencing (NGS): Doing More with Less

Nikas IP, Mountzios G, Sydney GI, Ioakim KJ, Won JK, Papageorgis P. | Cancers (Basel). 2022 Jan 13

2021

Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer

Mountzios G, Samantas E, Senghas K, Zervas E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, Athanasiadis I, Gaissmaier L, Elshiaty M, Daniello L, Christopoulou A, Pentheroudakis G, Lianos E, Linardou H, Kriegsmann K, Kosmidis P, El Shafie R, Kriegsmann M, Psyrri A, Andreadis C, Fountzilas E, Heussel CP, Herth FJ, Winter H, Emmanouilides C, Oikonomopoulos G, Meister M, Muley T, Bischoff H, Saridaki Z, Razis E, Perdikouri EI, Stenzinger A, Boukovinas I, Reck M, Syrigos K, Thomas M, Christopoulos P. | ESMO Open. 2021 Oct

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Pa-tients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece

Mountzios G, Lampaki S, Koliou GA, Vozikis A, Kontogiorgos I, Papantoniou P, Koufaki MI, Res E, Boutis A, Christopoulou A, Pastelli N, Grivas A, Aravantinos G, Lalla E, Oikonomopoulos G, Koumarianou A, Spyratos D, Bafaloukos D, Rigakos G, Papakotoulas P, Fountzilas G, Linardou H. | Lung Cancer (Auckl). 2021 Aug 30

Lung Cancer in Greece

Mountzios G, Gkiozos I, Stratakos G, Pissakas G, Charpidou A, Toukfetzian L, Vamvakaris I, Syrigos K. | J Thorac Oncol. 2021 Jul

A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The 'LUNGFUL' Study

Mountzios G, Koumarianou A, Bokas A, Mavroudis D, Samantas E, Fergadis EG, Linardou H, Katsaounis P, Athanasiadis E, Karamouzis MV, Pentherou-dakis G, Lampaki S, Froudarakis ME, Perdikouri EA, Somarakis A, Papageorgiou F, Paparepa Z, Nikolaou A, Syrigos KN. | Cancers (Basel). 2021 Jun 25

Immunotherapy for the treatment of metastatic small cell lung cancer: Focus on pembrolizumab

Koulouris A, Mountzios G. | Expert Rev Clin Pharmacol. 2021 Jun

Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)

Ferrari A, Stark D, Peccatori FA, Fern L, Laurence V, Gaspar N, Bozovic-Spasojevic I, Smith O, De Munter J, Derwich K, Hjorth L, van der Graaf WTA, Soanes L, Jezdic S, Blondeel A, Bielack S, Douillard JY, Mountzios G, Saloustros E. | ESMO Open. 2021 Apr

Mediterranean Diet Implementation to Protect against Advanced Lung Cancer Index (ALI) Rise: Study Design and Preliminary Results of a Randomised Controlled Trial

Gioxari A, Tzanos D, Kostara C, Papandreou P, Mountzios G, Skouroliakou M. | Int J Environ Res Public Health. 2021 Apr 1

Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis

Metro G, Gili A, Signorelli D, De Toma A, Garaffa M, Galetta D, Economopoulou P, Friedlaender A, Jimenez B, Collazo-Lorduy A, Addeo A, Chiarini P, Costa C, Mountzios G, Roila F. | Clin Transl Oncol. 2021 Mar 16

Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy

Mountzios G, de Toma A, Economopoulou P, Friedlaender A, Banini M, Lo Russo G, Baxevanos P, Roila F, Banna GL, Christopoulou A, Jimenez B, Collazo-Lorduy A, Linardou H, Calles A, Galetta D, Addeo A, Camerini A, Pizzutilo P, Kosmidis P, Garassino MC, Proto C, Signorelli D, Metro G. | Clin Lung Cancer. 2021 Mar

2020

Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy

Metro G, Banna GL, Signorelli D, Gili A, Galetta D, Galli G, Economopoulou P, Roila F, Friedlaender A, Camerini A, Christopoulou A, Cantale O, De Toma A, Pizzutilo P, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Giannarelli D, Mountzios G, Addeo A. | J Immunother. 2020 Nov/Dec

Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metas-tases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%

Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab

Friedlaender A, Metro G, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Mountzios G, Garassino MC, Addeo A. | Acta Oncol. 2020 Sep

Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group

Fountzilas E, Koliou GA, Vozikis A, Rapti V, Nikolakopoulos A, Boutis A, Christopoulou A, Kontogiorgos I, Karageorgopoulou S, Lalla E, Tryfonopoulos D, Boukovinas I, Rapti C, Nikolaidi A, Karteri S, Moirogiorgou E, Binas I, Mauri D, Aravantinos G, Zagouri F, Saridaki Z, Psyrri A, Bafaloukos D, Koumarianou A, Res E, Linardou H, Mountzios G, Razis E, Fountzilas G, Koumakis G. ESMO Open. 2020 Aug

Impact of Bevacizumab Versus Erlotinib on Tumor Metrics in Patients With Previ-ously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group

Mountzios G, Mavropoulou X, Koliou GA, Linardou H, Samantas E, Kosmidis P, Fountzilas G, Charitandi A, Kalogera-Fountzila A. | Anticancer Res. 2020 Apr

2019

Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.

Metro G, Addeo A, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Rey Cobo J, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Garassino MC, Mountzios G. | J Thorac Dis. 2019 Dec

Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment

Linardou H, Kotoula V, Kouvatseas G, Mountzios G, Karavasilis V, Samantas E, Kalogera-Fountzila A, Televantou D, Papadopoulou K, Mavropoulou X, Daskalaki E, Zaramboukas T, Efstratiou I, Lampaki S, Rallis G, Res E, Syrigos KN, Kosmidis PA, Pectasides D, Fountzilas G. | Cancer Genomics Proteomics. 2019 Nov-Dec

Position of an international panel of lung cancer experts on the decision for expan-sion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration

Mountzios G, Remon J, Novello S, Blais N, Califano R, Cufer T, Dingemans AM, Liu SV, Peled N, Pennell NA, Reck M, Rolfo C, Tan D, Vansteenkiste J, West H, Besse B. | Ann Oncol. 2019 Nov 1

Prognostic Significance of IGF-1 Signalling Pathway in Patients With Advanced Non-small Cell Lung Cancer

Kotsantis I, Economopoulou P, Psyrri A, Maratou E, Pectasides D, Gogas H, Kentepozidis N, Mountzios G, Dimitriadis G, Giannouli S. | Anticancer Res. 2019 Aug

Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey

Li CK, Dalvi R, Yonemori K, Ariffin H, Lyu CJ, Farid M, Gonzales-Santos JRN, Zhou Q, Bielack S, Brugieres L, Blondeel A, Essiaf S, Peccatori FA, Jezdic S, Stark DP, Douillard JY, Saloustros E, Mountzios G. | ESMO Open. 2019 Jun 6

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update

Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, Mountzios G, Peswani N, Porter L, Tanaka TN, Trifirò G, Yang H, Lazo-Langner A. | J Clin Oncol. 2019 May 20

Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab

Mountzios G, Kotoula V, Kolliou GA, Papadopoulou K, Lazaridis G, Christodoulou C, Pentheroudakis G, Skondra M, Koutras A, Linardou H, Razis E, Papakostas P, Chrisafi S, Aravantinos G, Nicolaou I, Goussia A, Kalogeras K, Pectasides D, Fountzilas G. | ESMO Open. 2019 May 12

Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update

Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, Mountzios G, Peswani N, Porter L, Tanaka TN, Trifirò G, Yang H, Lazo-Langner A. | Blood Adv. 2019 Apr 23

Recent clinical trials of immunotherapy in non-small-cell lung cancer

Gkolfinopoulos S, Mountzios G | Immunotherapy. 2019 Apr

2018

Treating EGFR-Mutated Oncogene-Addicted Advanced Non-Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities

Fountzilas E, Levva S, Mountzios G, Polychronidou G, Maniadakis N, Kotoula V, Fountzilas G. | J Glob Oncol. 2018 Sep;4

Atezolizumab Treatment of Nonsquamous NSCLC

Mountzios G, Calles A, Addeo A. | N Engl J Med. 2018 Sep 20

The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.

Papadimitriou M, Mountzios G, Papadimitriou CA. | Cancer Treat Rev. 2018 Jun

Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer.

Gkolfinopoulos S, Mountzios G. | Ann Transl Med. 2018 Apr

Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs).

Mountzios G. | Ann Transl Med. 2018 Apr

Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau?

Baxevanos P, Mountzios G. | Ann Transl Med. 2018 Apr

The emerging treatment landscape of advanced non-small cell lung cancer.

Economopoulou P, Mountzios G. | Ann Transl Med. 2018 Apr

Lung cancer: biology and technology foster therapeutic innovation.

Mountzios G. | Ann Transl Med. 2018 Apr

Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?

Mountzios G. | Transl Lung Cancer Res. 2018 Apr

2017

Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis.

De Mello RA, Escriu C, Castelo-Branco P, Cabral PL, Mountzios G, Lopes GL, Madureira P. | Oncotarget. 2017 Dec

Dr. Giannis Mountzios: immunotherapy, an "earthquake" in the treatment of advanced lung cancer.

Ling N. | Transl Lung Cancer Res. 2017 Dec

The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey.

Saloustros E, Stark DP, Michailidou K, Mountzios G, Brugieres L, Peccatori FA, Jezdic S, Essiaf S, Douillard JY, Bielack S. | ESMO Open. 2017 Sep

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey.

Banerjee S, Califano R, Corral J, de Azambuja E, De Mattos-Arruda L, Guarneri V, Hutka M, Jordan K, Martinelli E, Mountzios G, Ozturk MA, Petrova M, Postel-Vinay S, Preusser M, Qvortrup C, Volkov MNM, Tabernero J, Olmos D, Strijbos MH. | Ann Oncol. 2017 Jul

2016

Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy.

Economopoulou P, Mountzios G. | Transl Lung Cancer Res. 2016 Dec

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. | ESMO Open. 2016 Sep

Future perspectives in cancer immunotherapy.

Tsiatas M, Mountzios G, Curigliano G. | Ann Transl Med. 2016 Jul

Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting.

Mountzios G, Linardou H, Kosmidis P. | Ann Transl Med. 2016 Jul

A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker.

Aguiar PN Jr, Santoro IL, Tadokoro H, de Lima Lopes G, Filardi BA, Oliveira P, Castelo-Branco P, Mountzios G, de Mello RA. | Immunotherapy. 2016 Sep

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G; ESMO/ASCO Global Curriculum Working Group. | Ann Oncol. 2016 Aug

Therapies in the pipeline for small-cell lung cancer.

Romanidou O, Imbimbo M, Mountzios G, Abidin A, Morgillo F, Califano R. | Br Med Bull. 2016 Sep

Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?

Califano R, Romanidou O, Mountzios G, Landi L, Cappuzzo F, Blackhall F. | Drugs. 2016 May

Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.

Metro G, Ricciuti B, Chiari R, Baretti M, Falcinelli L, Giannarelli D, Sidoni A, Mountzios G, Crinò L, Bellezza G, Rebonato A, Ferolla P, Toschi L. | Lung Cancer. 2016 May

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis.

Aguiar PN Jr, Santoro IL, Tadokoro H, de Lima Lopes G, Filardi BA, Oliveira P, Mountzios G, de Mello RA. | Immunotherapy. 2016

Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia.

Mountzios G, Aravantinos G, Alexopoulou Z, Timotheadou E, Matsiakou F, Christodoulou C, Laschos K, Galani E, Koutras A, Bafaloukos D, Linardou H, Pectasides D, Varthalitis I, Papakostas P, Kalofonos HP, Fountzilas G. | Mol Clin Oncol. 2016 Feb

Novel therapies for advanced squamous cell carcinoma of the lung.

Koutsoukos K, Mountzios G. | Future Oncol. 2016 Mar

Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.

Monteiro ID, Califano R, Mountzios G, de Mello RA. | Future Oncol. 2016 Feb

Teenagers and young adults with cancer in Europe: from national programmes to a European integrated coordinated project.

Stark D, Bielack S, Brugieres L, Dirksen U, Duarte X, Dunn S, Erdelyi DJ, Grew T, Hjorth L, Jazbec J, Kabickova E, Konsoulova A, Kowalczyk JR, Lassaletta A, Laurence V, Lewis I, Monrabal A, Morgan S, Mountzios G, Olsen PR, Renard M, Saeter G, van der Graaf WT, Ferrari A. | Eur J Cancer Care (Engl). 2016 May

2015

Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer.

Economopoulou P, Mountzios G, Pavlidis N, Pentheroudakis G. | Cancer Treat Rev. 2015 Jul

Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents.

Califano R, Morgillo F, De Mello RA, Mountzios G. | Ann Transl Med. 2015 Apr

Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.

Califano R, Abidin A, Tariq NU, Economopoulou P, Metro G, Mountzios G. | Cancer Treat Rev. 2015 May

Optimal management of the elderly patient with head and neck cancer: Issues regarding surgery, irradiation and chemotherapy.

Mountzios G | World J Clin Oncol. 2015 Feb

2014

Immunotherapy and lung cancer: current developments and novel targeted therapies.

Domingues D, Turner A, Silva MD, Marques DS, Mellidez JC, Wannesson L, Mountzios G, de Mello RA. | Immunotherapy.

Do elderly patients with non-small cell lung cancer get the best out of recent advances in first-line treatment? A comparative study in two tertiary cancer centers in Greece.

Bakogeorgos M, Mountzios G, Bournakis E, Economopoulou P, Kotsantis G, Fytrakis N, Kouvatseas G, Dimopoulos MA, Kentepozidis N. | J Geriatr Oncol. 2015 Mar

The case of the missed chest radiograph: bilateral mammary gland metastases mimicking multifocal primary breast cancer as the initial manifestation of non-small-cell lung cancer.

Mountzios G, Gyftopoulos A, Vlotinou E, Kentepozidis N. | J Thorac Oncol. 2014 Nov

The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact.

Mountzios G, Rampias T, Psyrri A. | Ann Oncol. 2014 Oct

Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes.

Mountzios G, Aivazi D, Kostopoulos I, Kourea HP, Kouvatseas G, Timotheadou E, Zebekakis P, Efstratiou I, Gogas H, Vamvouka C, Chrisafi S, Stofas A, Pentheroudakis G, Koutras A, Galani E, Bafaloukos D, Fountzilas G. | PLoS One. 2014 Mar

Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC.

Champiat S, Ileana E, Giaccone G, Besse B, Mountzios G, Eggermont A, Soria JC. | J Thorac Oncol. 2014 Feb

Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster.

Mountzios G, Pentheroudakis G, Carmeliet P. | Pharmacol Ther. 2014 Feb

2013

Chemotherapy compliance, tolerance and efficacy in elderly and non-elderly patients with metastatic colorectal cancer: a single institution comparative study.

Bakogeorgos M, Mountzios G, Kotsantis G, Economopoulou P, Fytrakis N, Kentepozidis N. | J BUON. 2013 Jul-Sep

Novel approaches for concurrent irradiation in locally advanced cervical cancer: platinum combinations, non-platinum-containing regimens, and molecular targeted agents.

Mountzios G, Soultati A, Pectasides D, Dimopoulos MA, Papadimitriou CA. | Obstet Gynecol Int.

Adrenal incidentalomas in cancer patients are not always "innocent": a case report and review of the literature.

Economopoulou P, Mountzios G, Kotsantis I, Bakogeorgos M, Ramfidis V, Kapiris I, Patsouris E, Kentepozidis N. | Case Rep Med.

Developments in the systemic treatment of metastatic cervical cancer.

Mountzios G, Soultati A, Pectasides D, Pectasides E, Dimopoulos MA, Papadimitriou CA. | Cancer Treat Rev. 2013 Aug

«Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer»

Mountzios G, Kostopoulos I, Kotoula V, Sfakianaki I, Fountzilas E, Markou K, Karasmanis I, Leva S, Angouridakis N, Vlachtsis K, Nikolaou A, Konstantinidis I, Fountzilas G. | PLoS One. 2013;8(1):e54048. doi: 10.1371/journal.pone.0054048. Epub 2013 Jan 24.

2012

«Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications»

Soultati A, Mountzios G, Avgerinou C, Papaxoinis G, Pectasides D, Dimopoulos MA, Papadimitriou C. | Cancer Treat Rev. 2012 Aug;38(5):473-83.

«Array-based pharmacogenomics of molecular-targeted therapies in oncology»

Sanoudou D, Mountzios G, Arvanitis DA, Pectasides D. | Pharmacogenomics J. 2012 Jun;12(3):185-96.

«Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group»

Mountzios G, Emmanouilidis C, Vardakis N, Kontopodis E, Hatzidaki D, Popis E, Karachaliou N, Kotsakis A, Agelidou M, Georgoulias V. | Lung Cancer. 2012 Jul;77(1):146-50.

«Bevacizumab in ovarian cancer.»

Mountzios G, Pentheroudakis G. | N Engl J Med. 2012 Mar 29;366(13):1257; author reply 1258.

«Developments in the systemic treatment of metastatic cervical cancer»

Mountzios G, Soultati A, Pectasides D, Pectasides E, Dimopoulos MA, Papadimitriou CA. | Cancer Treat Rev. 2012 Jun 22. [Epub ahead of print]

2011

«Developments in the systemic treatment of endometrial cancer»

Giannis Mountzios, Dimitrios Pectasides, Eftichia Kafantari, Eirini Pectasides, George Bozas, Meletios-A. Dimopoulos and Christos A. Papadimitriou. | Crit Rev Oncol Hematol. 2011 Sep;79(3):278-92

«Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data»

Mountzios G, Ramfidis V, Terpos E, Syrigos KN. | Clin Lung Cancer. 2011 Nov;12(6):341-9.

«A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer»

Mountzios G, Syrigos KN. | Drug Saf. 2011 Mar 1;34(3):175-86.

«Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer»

Mountzios I, Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Karadimou A, Tsiatas M, Papadimitriou C, Bamias A, Dimopoulos MA. | Urology. 2011 Mar;77(3):682-7.

«All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer»

Linardou H, Briasoulis E, Dahabreh IJ, Mountzios G, Papadimitriou C, Papadopoulos S, Bafaloukos D, Kosmidis P, Murray S.Cancer Treat Rev. | 2011 May;37(3):221-33

2010

«Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrogen-mediated vasodilatation»

Vassilakopoulou M, Mountzios G, Papamechael C, Protogerou A D, Aznaouridis K, Katsichti P, Venetsanou K, Dimopoulos M-A, Ikonomidis I, Papadimitriou C A. | Currently in press at J Pharm Sciences [January 2010]

2009

«Cisplatin-based chemotherapy for advanced seminoma: report of 52 cases treated in two institutions»

Mountzios Giannis, Bamias Aristotelis, Koutsoukou Vassiliki, Anastasiou Ioannis, Stravodimos Konstantinos, Antoniou Nikolaos, Papadopoulos Georgios, Pavlakis Georgios, Papassavas Pantelis and Dimopoulos Meletios-Athanasios. | J Cancer Res Clin Oncol. 2009; 135: 1495-1500

«Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid»

Giannis Mountzios, Evangelos Terpos, Konstantinos Syrigos, Christos Papadimitriou, Giorgos Papadopoulos, Aristotelis Bamias, Μyron Μavrikakis and Meletios-Athanassios Dimopoulos. | J Transl Res 2009 Dec; [Epub ahead of print]

«Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature»

S. Murray, H. Linardou, G. Mountzios, M. Manoloukos, S. Markaki, E. Eleutherakis-Papaiakovou, N. Nikitas, M.-A. Dimopoulos, and C. A. Papadimitriou. | Mut Res 2009 Dec; [Epub ahead of print].

«Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data»

Mountzios G, Dimopoulos MA, Soria JC, Sanoudou D, Papadimitriou CA. | Crit Rev Oncol Hematol. 2009 Nov 12. [Epub ahead of print]

Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study.

Mountzios G, Dimopoulos MA, Bamias A, Vourli G, Kalofonos H, Aravantinos G, Fountzilas G, Papadimitriou CA. | Ann Oncol. 2009 Aug: 20(8):1362-8

2008

«Endocardial metastases as the only site of relapse in a patient with bladder carcinoma: A case report and review of the literature»

Mountzios G, Bamias A, Dalianis A, Danias P, Pantelidaki E, Nanas J, Dimopoulos MA. | Int J Cardiol. 2008 Nov 29. [Epub ahead of print]

«Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer»

Mountzios G, Dimopoulos MA, Papadimitriou C. | Biomark Insights. 2008 Apr 17;3:219-226

«Mechanisms of Disease: signal transduction in lung carcinogenesis: a comparison of smokers and never-smokers»

Mountzios G, Fouret P, Soria JC. | Nat Clin Pract Oncol. 2008 Oct;5(10):610-8.

«Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers»

Mountzios G, Planchard D, Besse B, Validire P, Girard P, Devisme C, Dimopoulos MA, Soria JC, Fouret P. | Clin Cancer Res. 2008 Jul 1;14(13):4096-102.

«Aurora kinases as targets for cancer therapy»

Mountzios G, Terpos E and Dimopoulos MA. | Cancer Treat Rev. 2008 Apr;34(2):175-82.

«Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model»

Mountzios G, Bamias A, Voulgaris Z, Rodolakis A, Vlahos G, Gourgoulis G, Papaiakovou EE, Giannopoulos A. | Gynecol Oncol. 2008 Jan;108(1):130-5.

2007

“Abnormal bone remodeling process is due to an imbalance in the Receptor Activator of Nuclear Factor–kB Ligand (RANKL)/Osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.

Giannis Mountzios, Meletios-Athanassios Dimopoulos, Aristotelis Bamias, George Papadopoulos, Efstathios Kastritis, Konstantinos Syrigos, George Pavlakis and Evangelos Terpos. 251 General Airforce Hospital, Medical Oncology Dpt and University of Athens School of Medicine, “Alexandra” Hospital, Dpt. of Oncology. | Acta Oncol. 2007;46(2):221-9.

«ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer»

Olaussen KA, Mountzios G and Soria JC. | Curr Opin Pulm Med. 2007 Jul;13(4):284-9.

«Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma»

Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P. | Clin Cancer Res. 2007 Jul 1;13(13):3855-9.

Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer.

Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon Mountzios G, Validire P, Domont J, Girard P, Grunenwald D, Le Chevalier T, Soria JC. | Ann Oncol. 2007 Jun:18(6):1043-50.

2006

“Recurrent ovarian cancer metastatic to the sternum, costae, and thoracic wall after prolonged treatment with platinum-based chemotherapy: A case report and review of the literature”

G.Pavlakis, G. Mountzios, , E. Terpos, A. Leivaditou, G. Papadopoulos, P. Papassavas 251 General Airforce Hospital, Medical Oncology Dpt, Athens, Greece. | Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:299-303.

“Concurrent Development of Testicular Seminoma and Choriocarcinoma of the Superior Mediastinum, Presented as Cervical Mass: A Case Report and Implications about Pathogenetic Mechanisms"

Giannis Mountzios, Evangelos Terpos, George Sakorafas, Alexandra Leivaditou,George Papadopoulos, George Pavlakis, Evangelos Syrigos and Meletios-Athanasios Dimopoulos 251 General Airforce Hospital, Medical Oncology Dpt, Athens, Greece. | BMC Clin Pathol. 2006 Nov 20;6(1):8

“Advanced non-small-cell lung cancer: 'triplets' better than 'doublets'?”

Giannis Mountzios and Jean-Charles Soria Institut Gustave Roussy, Dpt of Medicine, Villejuif, France. | Nat Clin Pract Oncol. 2006 Sep;3(9):476-7.

Συμμετοχή στη συγγραφή Διεθνών Επιστημονικών Συγγραμμάτων

Hellenic Society of Medical Oncology publication: «Forum of Clinical Oncology» - Chapter: «Pharmacogenomics and Molecular targeted Therapy»

- | Hellenic Society for Medical Oncology Greece Ó 2008

«Targeted Therapies in Oncology» - Chapter: «Overview of existing therapies»

Pr. Giuseppe Giaccone and Pr. Jean -Charles Soria. | Informa Healthcare USA Ó 2007

«Hellenic Academy of Medical Oncology» Book Series - Chapter: «Chemotherapy for early-stage ovarian cancer» And «Chemotherapy for hormone-refractory prostate cancer»

Dr. Briasoulis and Dr. Siamantas | Hellenic Society for Medical Oncology Greece Ó 2007-9

«European Society for Medical Oncology (ESMO) Handbook of Oncological emergencies» - Chapter: «Nausea and Vomiting»

Pr. D. Sjivers | Taulor and Francis Group Ó 2006